Andere Sprachen Corcept Therapeutics Incorporated

Aktien

529882

US2183521028

CORT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
23.32 ^USD	-0.21%		+1.39%	-28.20%

29.04.	Corcept Therapeutics Incorporated schließt Rekrutierung in Phase 4 Catalyst-Studie ab	CI
22.04.	Corcept Therapeutics Incorporated gibt positive Ergebnisse des Open-Label-Teils der zulassungsrelevanten Phase 3 GRACE-Studie bei Patienten mit Cushing-Syndrom bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Corcept Completes Enrollment in Phase 4 CATALYST Trial	29.04.
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial	29.04.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call	24.04.
Corcept Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing's syndrome	23.04.
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome	22.04.
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	22.04.
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)	15.04.
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	15.04.
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	08.04.
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	08.04.
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome	01.04.
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	01.04.
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	21.03.
Sector Update: Health Care Stocks Advance Friday Afternoon	16.02.
Sector Update: Health Care Stocks Gain Pre-Bell Friday	16.02.
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell	16.02.
Sector Update: Health Care	16.02.
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance	15.02.
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	15.02.
Corcept: Q4 Earnings Snapshot	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Corcept Therapeutics Incorporated

Aktien

529882

US2183521028

CORT

Andere Sprachen

Filter